CD28 (P10747) variants and mutations
CD28 (also known as P10747) is a human protein-coding gene encoding a t-cell-specific surface glycoprotein protein. It provides a key costimulatory signal when T cells recognize antigen, promoting IL-2 production, survival, metabolism, and clonal expansion. Modulating CD28-family signaling is central to therapies that either enhance antitumor immunity or suppress unwanted immune activation. This analysis covers 481 CD28 variants and mutations. Of these, 95% have computational variant effect predictions. Disease context includes HIV infectious disease, asthma, and immunodeficiency 123 with HPV-related verrucosis. Example CD28 variants include M1L, M1T, and M1I.
Variant analysis overview
- Gene: CD28
- Protein: P10747
- UniProt accession: P10747
- Organism: Homo sapiens
- Variants analyzed: 481
- Variant scope: all variants
- Completed: 2026-08-20
Variant and mutation evidence
- Variant composition: 216 unspecified-consequence records; 130 missense variants; 107 synonymous variants; 11 frameshift variants; 2 in-frame deletions; 3 stop-gained variants; 4 splice-region variants; 1 in-frame insertions; 1 stop retained variant; 1 stop lost; 5 substitution
- Prediction scores: 458 variants have prediction scores (95% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: HIV infectious disease, asthma, immunodeficiency 123 with HPV-related verrucosis, cancer, inflammatory bowel disease, autoimmune disease, hypothyroidism, psoriasis, urolithiasis, alcohol drinking, premature birth, celiac disease.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 1 domains; 8 post-translational modification sites.
- Structural context: 256 variants have structural context.
- PTM context: 17 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable CD28 variants
Examples include M1L, M1T, M1I, L2F, L2I, L2H, L2L, R3K. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1L (p.Met1Leu), gnomAD 2-203706551-A-T, CADD 11.10, SIFT 0.40
- M1T (p.Met1Thr), gnomAD 2-203706552-T-C, CADD 13.80, SIFT 0.16
- M1I (p.Met1Ile), gnomAD 2-203706553-G-A, CADD 13.60, SIFT 0.30
- L2F (p.Leu2Phe), TOPMed rs1693164875
- L2I (p.Leu2Ile), NCI-TCGA TCGA novel, MetaLR 0.08, MetaSVM -0.93, Variant assessed as somatic; moderate impact.
- L2H (p.Leu2His), gnomAD 2-203706701-T-A, REVEL 0.25, MetaLR 0.30
- L2L (p.Leu2Leu), rs142565527, gnomAD 2-203706702-C-G, CADD 9.61
- R3K (p.Arg3Lys), ExAC rs755944886, gnomAD rs755944886, REVEL 0.23, MetaLR 0.39
- R3M (p.Arg3Met), ExAC rs755944886, gnomAD rs755944886
- R3R (p.Arg3Arg), rs1290771258, gnomAD 2-203706705-G-A, CADD 10.10
- L4L (p.Leu4Leu), rs1338789266, gnomAD 2-203706706-C-T, CADD 9.80
- L5P (p.Leu5Pro), ExAC rs780493602, TOPMed rs780493602, gnomAD rs780493602, REVEL 0.61, MetaLR 0.69
- L5L (p.Leu5Leu), gnomAD 2-203706538-G-A, CADD 12.60
- L5F (p.Leu5Phe), gnomAD 2-203706538-G-T, CADD 12.10, SIFT 0.32
- A7T (p.Ala7Thr), NCI-TCGA TCGA novel, MetaLR 0.37, MetaSVM -0.74, Variant assessed as somatic; moderate impact.
- A7V (p.Ala7Val), NCI-TCGA TCGA novel, CADD 12.90, SIFT 0.32, Variant assessed as somatic; moderate impact.
- A7S (p.Ala7Ser), gnomAD 2-203706542-G-T, CADD 2.51, SIFT 0.30
- A7D (p.Ala7Asp), rs1450433943, gnomAD 2-203706543-C-A, CADD 12.30, SIFT 0.06
- A7A (p.Ala7Ala), gnomAD 2-203706544-C-A, CADD 11.40
- A7E (p.Ala7Glu), rs200559188, gnomAD 2-203706573-C-A, CADD 4.10, SIFT 1.00
- L8F (p.Leu8Phe), 1000Genomes rs141027316, ESP rs141027316, ExAC rs141027316, TOPMed rs141027316, CADD 11.90, SIFT 0.05
- L8V (p.Leu8Val), 1000Genomes rs141027316, ESP rs141027316, ExAC rs141027316, TOPMed rs141027316, REVEL 0.43, MetaLR 0.57
- N9S (p.Asn9Ser), TOPMed rs1303625960, gnomAD rs1303625960, REVEL 0.23, MetaLR 0.39
- L10L (p.Leu10Leu), rs748721658, gnomAD 2-203706726-A-G, CADD 5.93
- F11L (p.Phe11Leu), gnomAD 2-203706727-T-C, REVEL 0.34, MetaLR 0.41
- F11F (p.Phe11Phe), rs1693166002, gnomAD 2-203706729-C-T, CADD 6.26
- P12L (p.Pro12Leu), ExAC rs202094371, TOPMed rs202094371, gnomAD rs202094371, CADD 4.50, SIFT 0.38
- P12T (p.Pro12Thr), gnomAD 2-203706527-C-A, CADD 15.10, SIFT 0.00
- P12A (p.Pro12Ala), rs1693159763, gnomAD 2-203706527-C-G, CADD 15.20, SIFT 0.00
- P12P (p.Pro12Pro), rs1559548001, gnomAD 2-203706529-T-C, CADD 15.90
- P12S (p.Pro12Ser), gnomAD 2-203706557-C-T, CADD 9.21, SIFT 0.70
- P12H (p.Pro12His), gnomAD 2-203706558-C-A, CADD 3.80, SIFT 0.04
- S13N (p.Ser13Asn), rs769258035, gnomAD 2-203706540-G-A, CADD 11.50, SIFT 0.28
- S13I (p.Ser13Ile), rs769258035, gnomAD 2-203706540-G-T, CADD 10.90, SIFT 0.03
- S13S (p.Ser13Ser), rs762309467, gnomAD 2-203706541-T-C, CADD 13.20
- I14V (p.Ile14Val), 1000Genomes rs146720297, ESP rs146720297, ExAC rs146720297, TOPMed rs146720297, REVEL 0.17, MetaLR 0.24
- I14I (p.Ile14Ile), gnomAD 2-203706550-C-T, CADD 13.00
- I14T (p.Ile14Thr), gnomAD 2-203706737-T-C, REVEL 0.38, MetaLR 0.48
- Q15K (p.Gln15Lys), Ensembl rs201768943, MetaLR 0.46, MetaSVM -0.68
- Q15R (p.Gln15Arg), rs199547990, ClinGen CA63675931, ClinVar RCV004433382, TOPMed rs199547990, REVEL 0.38, MetaLR 0.50, Uncertain significance, not specified
- V16I (p.Val16Ile), 1000Genomes rs150242792, ESP rs150242792, ExAC rs150242792, TOPMed rs150242792, REVEL 0.38, MetaLR 0.39
- V16V (p.Val16Val), gnomAD 2-203706577-G-T, CADD 12.80
- V16L (p.Val16Leu), gnomAD 2-203706742-G-C, REVEL 0.39, MetaLR 0.43
- T17I (p.Thr17Ile), 1000Genomes rs568613966, ExAC rs568613966, gnomAD rs568613966, REVEL 0.42, MetaLR 0.45
- T17K (p.Thr17Lys), 1000Genomes rs568613966, ExAC rs568613966, gnomAD rs568613966, REVEL 0.49, MetaLR 0.42
- T17T (p.Thr17Thr), gnomAD 2-203706747-A-G, CADD 22.40
- G18* (p.Gly18Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact., in IMD123
- G18E (p.Gly18Glu), ExAC rs747456956, gnomAD rs747456956, REVEL 0.12, MetaLR 0.12
- G18R (p.Gly18Arg), UniProt VAR 089967, MetaLR 0.44, MetaSVM 0.01, Pathogenic, Immunodeficiency 123 with HPV-related verrucosis
- G18C (p.Gly18Cys), rs1320110230, gnomAD 2-203706533-G-T, CADD 15.10, SIFT 0.00
- G18V (p.Gly18Val), gnomAD 2-203706534-G-T, CADD 16.60, SIFT 0.00
- p.Gly14 Met15del, gnomAD 2-203706561-AGGGG, CADD 6.54
- G18G (p.Gly18Gly), rs767763807, gnomAD 2-203706565-G-T, CADD 7.50
- N19D (p.Asn19Asp), ExAC rs200799799, TOPMed rs200799799, gnomAD rs200799799, REVEL 0.22, MetaLR 0.39, Uncertain significance, not specified
- N19K (p.Asn19Lys), Ensembl rs887810818
- N19N (p.Asn19Asn), gnomAD 2-203726637-C-T, CADD 8.21
- K20M (p.Lys20Met), ExAC rs781492330, gnomAD rs781492330, REVEL 0.55, MetaLR 0.64
- K20* (p.Lys20Ter), gnomAD 2-203706555-G-GC, CADD 13.30
- K20R (p.Lys20Arg), gnomAD 2-203706561-A-G, CADD 9.93, SIFT 0.81
- K20N (p.Lys20Asn), gnomAD 2-203706562-G-T, CADD 5.18, SIFT 0.18
- L22S (p.Leu22Ser), Ensembl rs2106119967
- L22V (p.Leu22Val), ExAC rs748989473, gnomAD rs748989473, MetaLR 0.43, MetaSVM -0.44
- L22W (p.Leu22Trp), gnomAD 2-203726641-AT-A, CADD 28.60
- L22L (p.Leu22Leu), rs748989473, gnomAD 2-203726644-T-C, CADD 9.45
- V23M (p.Val23Met), rs1188026727, gnomAD 2-203706581-G-A, CADD 14.50, SIFT 0.08
- V23V (p.Val23Val), rs1581494139, gnomAD 2-203706589-G-T, CADD 11.50
- V23A (p.Val23Ala), gnomAD 2-203726648-T-C, REVEL 0.55, MetaLR 0.69
- K24K (p.Lys24Lys), rs768238717, gnomAD 2-203726652-G-A, CADD 8.66
- Q25* (p.Gln25Ter), rs780780414, gnomAD 2-203706605-C-T, CADD 10.40
- Q25L (p.Gln25Leu), gnomAD 2-203706606-A-T, CADD 9.10, SIFT 0.49
- Q25H (p.Gln25His), rs565497008, gnomAD 2-203706607-G-T, CADD 13.00, SIFT 0.30
- S26* (p.Ser26Ter), Ensembl rs202067202, CADD 33.00
- S26L (p.Ser26Leu), cosmic curated COSV60731, Ensembl rs202067202, REVEL 0.24, MetaLR 0.27
- S26T (p.Ser26Thr), rs757088307, gnomAD 2-203706602-T-A, CADD 7.29, SIFT 0.26
- S26P (p.Ser26Pro), rs757088307, gnomAD 2-203706602-T-C, CADD 7.72, SIFT 0.28
- S26S (p.Ser26Ser), rs199844145, gnomAD 2-203726658-G-A, CADD 5.12
- P27P (p.Pro27Pro), rs138722381, gnomAD 2-203726661-C-G, CADD 5.99
- P27T (p.Pro27Thr), rs772079144, []
- M28I (p.Met28Ile), Ensembl rs1005123826, REVEL 0.07, MetaLR 0.40
- M28L (p.Met28Leu), ExAC rs771698017, TOPMed rs771698017, gnomAD rs771698017, REVEL 0.04, MetaLR 0.19
- M28V (p.Met28Val), ExAC rs771698017, TOPMed rs771698017, gnomAD rs771698017, REVEL 0.04, MetaLR 0.24
- M28W (p.Met28Trp), rs769766350, gnomAD 2-203706565-GA-G, CADD 7.86
- M28T (p.Met28Thr), gnomAD 2-203706567-T-C, CADD 4.40, SIFT 0.04
- L29I (p.Leu29Ile), ExAC rs773299801, TOPMed rs773299801, gnomAD rs773299801, REVEL 0.41, MetaLR 0.61
- L29L (p.Leu29Leu), gnomAD 2-203706611-T-C, CADD 8.80
- V30I (p.Val30Ile), gnomAD 2-203726668-G-A, REVEL 0.14, MetaLR 0.31
- V30A (p.Val30Ala), gnomAD 2-203726669-T-C, REVEL 0.35, MetaLR 0.42
- A31T (p.Ala31Thr), gnomAD rs1386535030, REVEL 0.05, MetaLR 0.32
- A31V (p.Ala31Val), ExAC rs760627956, TOPMed rs760627956, gnomAD rs760627956, REVEL 0.03, MetaLR 0.16
- A31P (p.Ala31Pro), rs1693161829, gnomAD 2-203706582-TG-T, CADD 11.50
- A31A (p.Ala31Ala), rs752155336, gnomAD 2-203706586-C-T, CADD 8.21
- A31E (p.Ala31Glu), gnomAD 2-203706615-C-A, CADD 10.20, SIFT 0.15
- A31G (p.Ala31Gly), gnomAD 2-203726672-C-G, REVEL 0.16, MetaLR 0.45
- Y32H (p.Tyr32His), gnomAD 2-203726674-T-C, REVEL 0.17, MetaLR 0.21
- Y32Y (p.Tyr32Tyr), rs143716553, gnomAD 2-203726676-C-T, CADD 0.05
- D33N (p.Asp33Asn), rs1371617402, NCI-TCGA Cosmic COSV6073, cosmic curated COSV60730, TOPMed rs1371617402, REVEL 0.03, MetaLR 0.12, Variant assessed as somatic; moderate impact.
- D33D (p.Asp33Asp), rs767248888, gnomAD 2-203706595-C-T, CADD 16.10
- D33E (p.Asp33Glu), rs767248888, gnomAD 2-203706595-C-A, CADD 15.70, SIFT 1.00
- D33Y (p.Asp33Tyr), gnomAD 2-203726677-G-T, REVEL 0.24, MetaLR 0.45
- N34D (p.Asn34Asp), gnomAD rs1263146496, REVEL 0.12, MetaLR 0.40
- N34S (p.Asn34Ser), gnomAD 2-203726681-A-G, REVEL 0.20, MetaLR 0.35
- N34N (p.Asn34Asn), rs564230998, gnomAD 2-203726682-T-C, CADD 0.24
- A35E (p.Ala35Glu), cosmic curated COSV99048, TOPMed rs1202305808, gnomAD rs1202305808, REVEL 0.03, MetaLR 0.11
- A35V (p.Ala35Val), rs1202305808, NCI-TCGA Cosmic COSV1001, cosmic curated COSV10014, NCI-TCGA Cosmic COSV9904, REVEL 0.13, MetaLR 0.18, Variant assessed as somatic; moderate impact.
- A35A (p.Ala35Ala), rs41272649, gnomAD 2-203726685-G-A, CADD 0.67
- N37T (p.Asn37Thr), rs769540080, gnomAD 2-203726688-CA-C, CADD 24.80
- N37S (p.Asn37Ser), gnomAD 2-203726690-A-G, REVEL 0.09, MetaLR 0.23
- L38I (p.Leu38Ile), gnomAD 2-203726692-C-A, REVEL 0.38, MetaLR 0.52
- L38F (p.Leu38Phe), gnomAD 2-203726692-C-T, REVEL 0.39, MetaLR 0.49
- L38V (p.Leu38Val), gnomAD 2-203726692-C-G, REVEL 0.31, MetaLR 0.41
- L38L (p.Leu38Leu), rs765419358, gnomAD 2-203726694-T-C, CADD 3.13
- S39T (p.Ser39Thr), rs551715108, ClinGen CA2066882, ClinVar RCV004078888, ExAC rs551715108, REVEL 0.06, MetaLR 0.28, Uncertain significance, not specified
- C40S (p.Cys40Ser), gnomAD 2-203706531-G-C, CADD 17.30, SIFT 0.00
- C40C (p.Cys40Cys), rs1199334347, gnomAD 2-203706532-T-C, CADD 14.30
- C40Y (p.Cys40Tyr), gnomAD 2-203706555-G-A, CADD 15.00, SIFT 0.08
- C40F (p.Cys40Phe), gnomAD 2-203706555-G-T, CADD 14.40, SIFT 0.07
- K41R (p.Lys41Arg), gnomAD 2-203726702-A-G, REVEL 0.04, MetaLR 0.19
- K41T (p.Lys41Thr), gnomAD 2-203726702-A-C, REVEL 0.12, MetaLR 0.23
- Y42* (p.Tyr42Ter), Ensembl rs866326114
- Y42F (p.Tyr42Phe), ExAC rs758484234, gnomAD rs758484234, REVEL 0.52, MetaLR 0.45
- S43C (p.Ser43Cys), gnomAD 2-203726708-C-G, REVEL 0.06, MetaLR 0.15
- Y44H (p.Tyr44His), TOPMed rs1174848807, MetaLR 0.07, MetaSVM -1.03
- Y44Y (p.Tyr44Tyr), rs762842404, gnomAD 2-203726712-C-T, CADD 8.55
- N45D (p.Asn45Asp), Ensembl rs201776549, REVEL 0.19, MetaLR 0.34
- N45K (p.Asn45Lys), gnomAD 2-203726715-T-A, REVEL 0.34, MetaLR 0.57
- L46F (p.Leu46Phe), gnomAD 2-203726716-C-T, REVEL 0.15, MetaLR 0.32
- L46L (p.Leu46Leu), rs200104007, gnomAD 2-203726718-C-T, CADD 8.82
- F47V (p.Phe47Val), gnomAD 2-203726719-T-G, REVEL 0.25, MetaLR 0.30
- F47F (p.Phe47Phe), rs752091786, gnomAD 2-203726721-C-T, CADD 8.32
- S48P (p.Ser48Pro), gnomAD rs1422953731, REVEL 0.10, MetaLR 0.34
- S48S (p.Ser48Ser), gnomAD 2-203726724-A-C, CADD 6.18
- R49R (p.Arg49Arg), gnomAD 2-203726725-A-C, CADD 12.50
- E50G (p.Glu50Gly), gnomAD 2-203726725-A-AG, CADD 27.50
- F51L (p.Phe51Leu), gnomAD 2-203726731-T-C, REVEL 0.38, MetaLR 0.53
- R52Q (p.Arg52Gln), rs1179953211, NCI-TCGA Cosmic COSV6073, cosmic curated COSV60731, TOPMed rs1179953211, REVEL 0.51, MetaLR 0.44, Variant assessed as somatic; moderate impact.
- R52W (p.Arg52Trp), cosmic curated COSV10465, ExAC rs781705879, TOPMed rs781705879, gnomAD rs781705879, REVEL 0.72, MetaLR 0.62
- A53T (p.Ala53Thr), gnomAD rs1355605919, REVEL 0.24, MetaLR 0.40
- A53H (p.Ala53His), gnomAD 2-203726734-CG-C, CADD 23.80
- A53V (p.Ala53Val), gnomAD 2-203726738-C-T, REVEL 0.22, MetaLR 0.18
- S54F (p.Ser54Phe), NCI-TCGA TCGA novel, REVEL 0.62, MetaLR 0.69, Variant assessed as somatic; moderate impact.
- S54Y (p.Ser54Tyr), gnomAD rs1457896779, REVEL 0.58, MetaLR 0.69
- L55F (p.Leu55Phe), gnomAD 2-203726743-C-T, REVEL 0.38, MetaLR 0.47
- L55L (p.Leu55Leu), rs1693759920, gnomAD 2-203726745-T-G, CADD 2.28
- H56Y (p.His56Tyr), Ensembl rs775569256, MetaLR 0.05, MetaSVM -0.99
- K57N (p.Lys57Asn), NCI-TCGA Cosmic COSV6073, cosmic curated COSV60731, REVEL 0.49, MetaLR 0.49, Variant assessed as somatic; moderate impact.
- K57K (p.Lys57Lys), gnomAD 2-203726751-A-G, CADD 7.77
- G58R (p.Gly58Arg), gnomAD 2-203726752-G-C, REVEL 0.40, MetaLR 0.30
- L59V (p.Leu59Val), gnomAD 2-203726755-C-G, REVEL 0.15, MetaLR 0.10
- L59L (p.Leu59Leu), rs1292144609, gnomAD 2-203726757-G-C, CADD 1.46
- D60G (p.Asp60Gly), TOPMed rs1347784700, gnomAD rs1347784700, REVEL 0.50, MetaLR 0.64
- D60D (p.Asp60Asp), rs1693760211, gnomAD 2-203726760-T-C, CADD 2.48
- S61N (p.Ser61Asn), ExAC rs35290181, TOPMed rs35290181, gnomAD rs35290181, REVEL 0.20, MetaLR 0.18
- S61G (p.Ser61Gly), gnomAD 2-203726761-A-G, REVEL 0.11, MetaLR 0.05
- S61T (p.Ser61Thr), gnomAD 2-203726762-G-C, REVEL 0.17, MetaLR 0.16
- A62S (p.Ala62Ser), 1000Genomes rs187859903, ExAC rs187859903, TOPMed rs187859903, gnomAD rs187859903, REVEL 0.08, MetaLR 0.07
- A62T (p.Ala62Thr), 1000Genomes rs187859903, ExAC rs187859903, TOPMed rs187859903, gnomAD rs187859903, REVEL 0.09, MetaLR 0.10
- A62V (p.Ala62Val), ExAC rs771716313, gnomAD rs771716313, REVEL 0.11, MetaLR 0.12
- A62A (p.Ala62Ala), rs369798043, gnomAD 2-203726766-T-C, CADD 1.54
- V63M (p.Val63Met), cosmic curated COSV60731, TOPMed rs988481268, gnomAD rs988481268, REVEL 0.34, MetaLR 0.60
- V63L (p.Val63Leu), gnomAD 2-203726767-G-C, REVEL 0.24, MetaLR 0.40
- E64K (p.Glu64Lys), cosmic curated COSV60730, gnomAD rs1274571413, REVEL 0.47, MetaLR 0.45
- E64Q (p.Glu64Gln), gnomAD 2-203726770-G-C, REVEL 0.41, MetaLR 0.50
- E64E (p.Glu64Glu), gnomAD 2-203726772-A-G, CADD 9.18
- V65A (p.Val65Ala), NCI-TCGA TCGA novel, MetaLR 0.65, MetaSVM 0.38, Variant assessed as somatic; moderate impact.
- V65D (p.Val65Asp), gnomAD 2-203726774-T-A, REVEL 0.83, MetaLR 0.65
- C66C (p.Cys66Cys), rs1693764528, gnomAD 2-203726778-T-C, CADD 2.90
- V67I (p.Val67Ile), TOPMed rs1332317340, gnomAD rs1332317340, REVEL 0.05, MetaLR 0.15
- V68A (p.Val68Ala), ExAC rs746965559, TOPMed rs746965559, gnomAD rs746965559, REVEL 0.32, MetaLR 0.49
- V68I (p.Val68Ile), gnomAD 2-203726782-G-A, REVEL 0.20, MetaLR 0.33
- Y69Y (p.Tyr69Tyr), rs771041842, gnomAD 2-203726787-T-C, CADD 1.71
- G70G (p.Gly70Gly), rs56087636, gnomAD 2-203726790-G-A, CADD 3.00
- Y72H (p.Tyr72His), gnomAD rs1490784783, REVEL 0.18, MetaLR 0.33
- S73P (p.Ser73Pro), gnomAD rs1693765664, REVEL 0.20, MetaLR 0.18
- S73Y (p.Ser73Tyr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S73F (p.Ser73Phe), gnomAD 2-203726798-C-T, REVEL 0.24, MetaLR 0.27
- S73S (p.Ser73Ser), rs202236189, gnomAD 2-203726799-C-A, CADD 2.52
- Q74* (p.Gln74Ter), TOPMed rs1693765924
- Q74R (p.Gln74Arg), gnomAD 2-203726801-A-G, REVEL 0.07, MetaLR 0.06
- Q75E (p.Gln75Glu), ESP rs373696798, ExAC rs373696798, TOPMed rs373696798, gnomAD rs373696798, REVEL 0.04, MetaLR 0.26
- Q75K (p.Gln75Lys), ESP rs373696798, ExAC rs373696798, TOPMed rs373696798, gnomAD rs373696798, MetaLR 0.25, MetaSVM -0.93
Public CD28 analysis runs
- CD28 analysis run — CD28 (481 variants) — completed 2026-08-20